| 0.0036 -0.002 (-29.41%) | 08-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Bionano Genomics, Inc. specializes in delivering advanced software and integrated systems for genomic analysis. Central to its offerings is the Saphyr platform, an end-to-end solution facilitating structural variant analysis through optical genome mapping. This technology aids in comprehensive genome examination and illuminates the intricacies of genetic alterations and their biological roles. The Saphyr ecosystem comprises several critical components: the Saphyr instrument, a sophisticated single-molecule imager; the Saphyr Chip, a disposable unit housing nanochannel arrays essential for DNA linearization; and specialized Bionano Prep and DNA labeling kits, which supply the necessary reagents and detailed protocols for isolating and marking ultra-high molecular weight DNA. Beyond hardware, Bionano also supplies Saphyr and Bionano compute servers for data processing. Furthermore, its NxClinical software unifies the analysis and interpretation of genomic variations derived from both microarray and next-generation sequencing data, serving both cytogenetic and molecular genetic applications. The firm extends its capabilities to include a suite of testing and laboratory services. These encompass: FirstStepDx PLUS, a chromosomal microarray designed to uncover genetic origins in patients presenting with autism spectrum disorder, developmental delays, or intellectual disabilities. Specialized testing for Fragile X syndrome (FXS). NextStepDx PLUS, an exome sequencing assay aimed at detecting genetic variants linked to pediatric developmental conditions. EpiPanelDx PLUS, a targeted genetic panel for individuals suffering from seizures, infantile spasms, encephalopathy, or febrile seizures. A PGx test capable of identifying more than 60 alleles across 11 distinct genes. Established in 2003, Bionano Genomics maintains its principal operations in San Diego, California.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|